antimalarial, antimycobacterial and antiproliferative activity of phenyl substituted mixed tetraoxanes
Clicks: 247
ID: 256201
2003
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
247 views
31 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #55 of 151 articles by views in meditsinskaia radiologiia
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Mixed tetraoxanes of the 4-phenyl-substituted cyclohexyl-spirotetraoxacyclohexyl-spirocholate series have been prepared and evaluated as possible antimalarials, antiproliferatives and antimycobacterials. The activity of the (4R or S)-phenyl series against P. falciparum D6 and W2 strains was found to be at the level of artemisinin, with two compounds, the acid 4 and the amide 6, exhibiting encouraging anti-TB activity as well. Very promising in vitro results of the said tetraoxanes were obtained against solid tumours and, in some instances, the activity against a selected number of cell lines was higher than that of the antitumor drug paclitaxel.
| Reference Key |
solaja2003journalantimalarial,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;BOGDAN A. SOLAJA;DENNIS E. KYLE;DEJAN OPSENICA;WILBUR K. MILHOUS |
| Journal | meditsinskaia radiologiia |
| Year | 2003 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.